Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030-Reference-Cited by-同舟云学术

Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030

Published:2017-08 Issue:2 Volume:67 Page:419-420
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Dore Gregory J.,Grebely Jason

Publisher

Elsevier BV

Subject

Hepatology

Reference5 articles.

1. Real-world treatment for chronic hepatitis C infection in Germany. Analyses from drug prescription data, 2010–2015;Zimmermann;J Hepatol,2017

2. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial;Dore;Ann Intern Med,2016

3. Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study;Grebely;J Hepatol,2017

4. Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation;Martin;J Hepatol,2016

5. Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe;Marshall;J Hepatol,2017

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis;PLOS Medicine;2021-10-19

2. Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis;PLOS ONE;2021-02-11

3. Global hepatitis C elimination: an investment framework;The Lancet Gastroenterology & Hepatology;2020-10

4. Colombian experience in the management of hepatitis C;Liver International;2020-07-12

5. Innovative strategies for the elimination of viral hepatitis at a national level: A country case series;Liver International;2019-09-04